A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

Absence Seizures Clinical Trial

Official title:
A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)

Status Completed

Clinical Trial Summary

This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00545012
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2
Start date	May 2000
Completion date	May 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04615442` - ECV - Epihunter Clinical Validation	N/A
Completed	`NCT04439656` - Detecting Absence Seizures Using Eye Tracking
Recruiting	`NCT06093490` - Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings
Not yet recruiting	`NCT06310772` - Assessing Comorbidities in Epilepsy Using Eye Movement Recordings